恒瑞医药：1类创新药SHR-1918注射液获受理并纳入优先审评程序

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for its innovative drug SHR-1918 injection, which is now included in the priority review process [1] Group 1 - SHR-1918 injection is designed for the treatment of adult and adolescent patients aged 12 and above with homozygous familial hypercholesterolemia (HoFH) [1] - The drug is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), which works by inhibiting ANGPTL3 activity to lower serum triglycerides (TG) and LDL-C levels [1] - The total research and development investment for the related project has reached approximately 242 million yuan [1]